Remarkably reduced expression of FoxO3a in metaplastic colorectum, primary colorectal cancer and liver metastasis.
10.1007/s11596-013-1098-7
- Author:
Le-ya HE
1
;
Xin WEI
;
Lei DU
;
Lu LIU
;
Feng XU
;
Jiang MIN
;
Chuan LI
;
De-ding TAO
;
Quan CHEN
;
Jun-bo HU
;
Jian-ping GONG
Author Information
1. Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. heleyaduck@163.com
- Publication Type:Journal Article
- MeSH:
Cell Cycle Checkpoints;
Colon;
metabolism;
pathology;
Colorectal Neoplasms;
metabolism;
pathology;
Down-Regulation;
Female;
Forkhead Box Protein O3;
Forkhead Transcription Factors;
metabolism;
Humans;
Liver Neoplasms;
metabolism;
pathology;
secondary;
Male;
Metaplasia;
metabolism;
pathology;
Rectum;
metabolism;
pathology;
Tumor Cells, Cultured
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2013;33(2):205-211
- CountryChina
- Language:English
-
Abstract:
The forkhead family members of transcription factors (FoxOs) are expected to be potential cancer-related drug targets and thus are being extremely studied recently. In the present study, FoxO3a, one major member of this family, was identified to be down-regulated in colorectal cancer through micro-array analysis, which was confirmed by RT-PCR and Western blot in 28 patients. Moreover, immunohistochemistry (IHC) showed that the expression levels of FoxO3a were remarkably reduced in 99 cases of primary colorectal cancer, liver metastasis, and even in metaplastic colorectal tissue. IHC also revealed an exclusion of FoxO3a from the nucleus of most cells of tumor-associated tissues. Silencing FoxO3a by siRNA led to elevation of G2-M phase cells. We conclude that the downregulation of FoxO3a may greatly contribute to tumor development, and thus FoxO3a may represent a novel therapeutic target in colorectal cancer.
